Subscribe To
CLPT / ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q1 2022 Results - Earnings Call Transcript
CLPT News
By Seeking Alpha
June 5, 2023
ClearPoint Neuro: I Continue To Rate The Stock A 'Buy'
ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners a more_horizontal
By Seeking Alpha
May 11, 2023
ClearPoint Neuro, Inc. (CLPT) Q1 2023 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessand more_horizontal
By GlobeNewsWire
April 28, 2023
ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform more_horizontal
By Seeking Alpha
March 1, 2023
ClearPoint Neuro, Inc. (CLPT) Q4 2022 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessa more_horizontal
By Seeking Alpha
January 30, 2023
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash Burn
ClearPoint Neuro is a growth story and should be evaluated as such. I break down some of the growth factors that I consider most important. more_horizontal
By GlobeNewsWire
November 9, 2022
ClearPoint Neuro to Present at Upcoming Investor Conferences
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform more_horizontal
By Seeking Alpha
November 8, 2022
ClearPoint Neuro, Inc. (CLPT) Q3 2022 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Ale more_horizontal
By Seeking Alpha
July 25, 2022
ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval proce more_horizontal